AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2124651 — intervention group
Group type: COMPARATOR
Intervention: Conventional total parenteral nutrition with a Calorie/N ratio of about 150.
Number of subjects: 0
Study 7047460 — intervention group
Group type: EXPERIMENTAL
Intervention: Micrainin (meprobamate-acetylsalicylic acid)
Number of subjects: 16
Study 7047460 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (acetylsalicylic acid)
Number of subjects: 16
Study 31260548 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 2: Imitation
Number of subjects: 53
Study 31260548 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 1: Relating to People
Number of subjects: 53
Study 31260548 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 5: Object Use
Number of subjects: 53
Study 31260548 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Autism Rating Scale (CARS) - Item 4: Body Use
Number of subjects: 53
Study 29144879 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (n=25)
Number of subjects: 50
Study 29144879 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (n=25)
Number of subjects: 50
Study 29144879 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (35% hydrogen peroxide and 37% carbamide peroxide)
Number of subjects: 50
Study 25316378 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective patellar resurfacing
Number of subjects: 350
Study 25316378 — intervention group
Group type: COMPARATOR
Intervention: No resurfacing (control group)
Number of subjects: 350
Study 23907470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 % sorbate (SA)
Number of subjects: 20
Study 23907470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 % benzoate (BA)
Number of subjects: 20
Study 23907470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 % chlorhexidine (CHX)
Number of subjects: 20
Study 23907470 — intervention group
Group type: COMPARATOR
Intervention: 0.9 % saline (NaCl)
Number of subjects: 20
Study 18240868 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐α2b and lamivudine
Number of subjects: 0
Study 18240868 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐α2b monotherapy
Number of subjects: 0
Study 15110370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.7 microg/kg bolus in 2-mL balanced salt solution)
Number of subjects: 70
Study 15110370 — intervention group
Group type: COMPARATOR
Intervention: Control (2-mL balanced salt solution without analgesic)
Number of subjects: 70
Study 15110370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 15110370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl group
Number of subjects: 70
Study 11220058 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenstrual Symptom Management Program
Number of subjects: 0
Study 9093341 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow triggering (1 and 5 l/min) during pressure support ventilation (PSV) and assisted controlled mode (A/C)
Number of subjects: 0
Study 9093341 — intervention group
Group type: COMPARATOR
Intervention: Pressure triggering (-1 cm H2O) during pressure support ventilation (PSV) and assisted controlled mode (A/C)
Number of subjects: 0
Study 9093341 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow triggering (1 and 5 l/min) in A/C mode
Number of subjects: 0
Study 9093341 — intervention group
Group type: COMPARATOR
Intervention: Pressure triggering (-1 cm H2O)
Number of subjects: 0
Study 10171655 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis for the production of platelet rich plasma (PRP), 20% of circulating plasma volume sequestered prior to heparinization, reinfused 10 minutes after heparin reversal.
Number of subjects: 115
Study 10171655 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR) with no sequestration procedure.
Number of subjects: 115
Study 3759280 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day atenolol
Number of subjects: 45
Study 3759280 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day metoprolol
Number of subjects: 45
Study 3759280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day mepindolol
Number of subjects: 45
Study 30695166 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness intervention for 8 weeks via Wechat platform
Number of subjects: 123
Study 30695166 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 123
Study 30695166 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness intervention
Number of subjects: 123
Study 28779926 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 90
Study 28779926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28779926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 26234968 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured walking intervention
Number of subjects: 104
Study 26234968 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 104
Study 23845057 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual assessment plus new individualized lifestyle assessment and referral
Number of subjects: 0
Study 23845057 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle assessment and referral
Number of subjects: 0
Study 21849282 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated 2009 H1N1 influenza vaccine (25 μg)
Number of subjects: 120
Study 21849282 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated 2009 H1N1 influenza vaccine (49 μg)
Number of subjects: 120
Study 19543664 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 96
Study 19543664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 16772789 — intervention group
Group type: EXPERIMENTAL
Intervention: LapMentor training (n = 10)
Number of subjects: 19
Study 16772789 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 19
Study 15611462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 1297
Study 11321866 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin included in 'tight control' combination therapy
Number of subjects: 2
Study 9051818 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression cardiopulmonary resuscitation (ACD-CPR)
Number of subjects: 33
Study 9051818 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 33
Study 8512162 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients (simulated patients)
Number of subjects: 59
Study 3326701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 17354
Study 3326701 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17354
Study 3326701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17354
Study 30447506 — intervention group
Group type: COMPARATOR
Intervention: Intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (LDLPFC), 1800 pulses at 80% of motor threshold.
Number of subjects: 23
Study 30447506 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 23
Study 27871598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 44
Study 27871598 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 44
Study 24829298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauramin 10% (taurine PN)
Number of subjects: 74
Study 24829298 — intervention group
Group type: COMPARATOR
Intervention: Standard PN solution without taurine (control PN)
Number of subjects: 74
Study 22741449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil on demand
Number of subjects: 61
Study 22741449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 61
Study 22741449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg once daily
Number of subjects: 61
Study 22741449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 20538738 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 8907
Study 20538738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8907
Study 19256268 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for Crohn's disease
Number of subjects: 62
Study 19256268 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to surgery and pharmacological treatment
Number of subjects: 62
Study 15625257 — intervention group
Group type: COMPARATOR
Intervention: Diclectin (DCL) administered orally (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) the night before surgery, the morning of surgery, and upon hospital discharge.
Number of subjects: 146
Study 15625257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 15625257 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclectin (DCL)
Number of subjects: 146
Study 14658924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA (10-40 mg/day)
Number of subjects: 161
Study 14658924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 14658924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA
Number of subjects: 161
Study 10816529 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type EPEC strain
Number of subjects: 20
Study 10816529 — intervention group
Group type: COMPARATOR
Intervention: DeltaespB mutant strain
Number of subjects: 20
Study 8867198 — intervention group
Group type: EXPERIMENTAL
Intervention: Full cognitive‐behavioural treatment programme (CBT)
Number of subjects: 121
Study 8867198 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention condition (MI)
Number of subjects: 121
Study 1638876 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for coronary heart disease
Number of subjects: 20000
Study 6234282 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg 12 hourly)
Number of subjects: 110
Study 6234282 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid/citrate (1 sachet 8 hourly)
Number of subjects: 110
Study 31340804 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐i-based group treatment (10 weekly 90-min group sessions and scheduled telephone support)
Number of subjects: 19
Study 29414142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) - one standardized Behavioral Health Consultation visit followed by three ACT-based group visits and one group booster visit.
Number of subjects: 60
Study 29414142 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU) - educational pain management handouts based on standard cognitive behavioral treatment of pain.
Number of subjects: 60
Study 26772822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nx4 (Neurexan ®)
Number of subjects: 64
Study 26772822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24680051 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC‐II(C) multimedia kit
Number of subjects: 153
Study 24680051 — intervention group
Group type: COMPARATOR
Intervention: Healthy Habits for Life (HHL) control kit
Number of subjects: 153
Study 22170358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (400 μg) + vitamin B-12 (100 μg) supplementation
Number of subjects: 900
Study 22170358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 21058159 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication coaching intervention
Number of subjects: 22
Study 21058159 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 22
Study 17944890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) and fitness exercises, 60 minutes per session, twice a week for 3 months
Number of subjects: 70
Study 17944890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 17944890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) and fitness exercises
Number of subjects: 70
Study 16323317 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (IFNbeta‐1a)
Number of subjects: 172
Study 16323317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 11992180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus betamethasone dipropionate 0.05% cream (mid-high-potency steroid)
Number of subjects: 200
Study 11992180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus mometasone furoate 0.1% ointment (high-potency steroid)
Number of subjects: 200
Study 11992180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus diflorasone diacetate 0.05% ointment (high-potency steroid)
Number of subjects: 200
Study 11992180 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel alone
Number of subjects: 200
Study 9646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious attendance (once per week or more)
Number of subjects: 455
Study 9646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prayer or Bible study
Number of subjects: 455
Study 9646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic religious attitudes
Number of subjects: 455
Study 9646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious faith as a coping factor
Number of subjects: 455
Study 9646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious attendance
Number of subjects: 455
Study 8005121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg plus Amiloride 2.5 mg (H+Am)
Number of subjects: 308
Study 8005121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine slow release 20 mg (N)
Number of subjects: 308
Study 8005121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (At)
Number of subjects: 308
Study 8005121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg plus Chlorthalidone 6.25 mg (At+C)
Number of subjects: 308
Study 8005121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 308
Study 2511239 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH iv administration
Number of subjects: 19
Study 2511239 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 19
Study 1094965 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone 600 mg daily
Number of subjects: 20
Study 1094965 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 3.6 g daily
Number of subjects: 20
Study 1094965 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone (in uncontrolled study)
Number of subjects: 20
Study 31307665 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT + RS
Number of subjects: 275
Study 31307665 — intervention group
Group type: COMPARATOR
Intervention: RT + RS
Number of subjects: 275
Study 28034518 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence studies with both male and female subjects
Number of subjects: 12
Study 28034518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmax or AUC
Number of subjects: 12
Study 28034518 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual variability between sexes
Number of subjects: 12
Study 28034518 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence conclusions
Number of subjects: 12
Study 25572618 — intervention group
Group type: EXPERIMENTAL
Intervention: Online theory of planned behaviour (TPB)-based intervention
Number of subjects: 534
Study 25572618 — intervention group
Group type: COMPARATOR
Intervention: Information only group (control)
Number of subjects: 534
Study 23333201 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg/kg (Group I)
Number of subjects: 80
Study 23333201 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 40 mg/kg (Group II)
Number of subjects: 80
Study 23333201 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg (Group III)
Number of subjects: 80
Study 23333201 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.5 mg/kg (Group IV)
Number of subjects: 80
Study 21666065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet (F&V)
Number of subjects: 66
Study 21666065 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 66
Study 19845237 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgotul SSD
Number of subjects: 68
Study 19845237 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine
Number of subjects: 68
Study 16551910 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg)
Number of subjects: 150
Study 16551910 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron (12.5 mg)
Number of subjects: 150
Study 16551910 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron (12.5 mg) in carriers of the duplication of the CYP2D6 allele
Number of subjects: 150
Study 15142871 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis (mixed talc, mean particle size < 15 microm)
Number of subjects: 68
Study 15142871 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis (mixed talc)
Number of subjects: 68
Study 15142871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed talc
Number of subjects: 68
Study 15142871 — intervention group
Group type: COMPARATOR
Intervention: Graded talc
Number of subjects: 68
Study 11009242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 80
Study 11009242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study 8883233 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC chemotherapy (cyclophosphamide, epirubicin, 5-fluorouracil)
Number of subjects: 107
Study 8883233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron alone
Number of subjects: 107
Study 8883233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 107
Study 1395119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg)
Number of subjects: 503
Study 1395119 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 503
Study 1395119 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg b.d.)
Number of subjects: 503
Study 1395119 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (hydrochlorothiazide 50 mg and amiloride 5 mg)
Number of subjects: 503
Study 1395119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril with diuretic
Number of subjects: 503
Study 1395119 — intervention group
Group type: COMPARATOR
Intervention: Captopril with diuretic
Number of subjects: 503
Study 1395119 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with perindopril
Number of subjects: 503
Study 3903063 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy and supradiaphragmatic radiotherapy (40 Gy) for clinical stages IA and II2A
Number of subjects: 72
Study 3903063 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP or CVPP chemotherapy followed by laparotomy and radiotherapy for clinical stages II3+A and IIB
Number of subjects: 72
Study 3903063 — intervention group
Group type: EXPERIMENTAL
Intervention: No mediastinal radiotherapy for patients without mediastinal involvement
Number of subjects: 72
Study 3903063 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients studied
Number of subjects: 72
Study 3301699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polybacterial vaccine containing 1.5 X 10(9) killed Haemophilus influenzae per tablet
Number of subjects: 0
Study 3301699 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-monthly courses of oral polybacterial vaccine
Number of subjects: 0
Study 3301699 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased immunizing dose (60 fold) without non H. influenzae bacterial species
Number of subjects: 0
Study 3301699 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 29855331 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolbachia-infected Ae. aegypti mosquitoes
Number of subjects: 24
Study 29855331 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 24
Study 29138181 — intervention group
Group type: EXPERIMENTAL
Intervention: GIKI2 group (GIK with intensive insulin therapy for 24 hours)
Number of subjects: 772
Study 29138181 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK group (GIK with nonintensive insulin therapy)
Number of subjects: 772
Study 29138181 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 772
Study 29138181 — intervention group
Group type: EXPERIMENTAL
Intervention: GIKI2 group (GIK with intensive insulin therapy)
Number of subjects: 772
Study 26303048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 14
Study 26303048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24066604 — intervention group
Group type: EXPERIMENTAL
Intervention: Guizhi Fuling capsule high dose
Number of subjects: 240
Study 24066604 — intervention group
Group type: EXPERIMENTAL
Intervention: Guizhi Fuling capsule low dose
Number of subjects: 240
Study 24066604 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 240
Study 21397805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical proparacaine anesthetic 0.5%
Number of subjects: 34
Study 21397805 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear solution
Number of subjects: 34
Study 18512513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbonding group in the lesion area (NBL)
Number of subjects: 26
Study 18512513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbonding group in sound enamel (NBS)
Number of subjects: 26
Study 18512513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding group in the lesion area (BL)
Number of subjects: 26
Study 18512513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding group in sound enamel (BS)
Number of subjects: 26